Personalized Medicine At A Crossroads: Omapro Stumble At Advisory Committee Underscores Need For Better Genetic Testing Standards
Executive Summary
Companies developing cancer drugs that target tumors with specific mutations received a stark message from the Oncology Drugs Advisory Committee: they need to develop a valid genetic test for determining the eligibility of patients enrolled in their pivotal clinical trials or the new drug application will face tough sledding at the Food and Drug Administration